Hepatocellular adenoma secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:
An annual follow-up with [[Magnetic resonance imaging|MRI]] or [[ultrasound]] may be scheduled for female patients until [[menopause]].
An annual follow-up with [[Magnetic resonance imaging|MRI]] or [[ultrasound]] may be scheduled for female patients until [[menopause]].


==Hepatocellular Adenoma Secondary Prevention==
==Secondary Prevention==
An annual follow-up with [[Magnetic resonance imaging|MRI]] or [[ultrasound]] may be scheduled for female patients until [[menopause]], when the [[adenoma]] is < 5cm or [[Regression|regress]] to < 5cm after discontinuation of [[Oral contraceptive|oral contraceptive medications]].<ref>{{Cite journal
An annual follow-up with [[Magnetic resonance imaging|MRI]] or [[ultrasound]] may be scheduled for female patients until [[menopause]], when:<ref>{{Cite journal
  | author = [[Maarten G. Thomeer]], [[Mirelle Broker]], [[Joanne Verheij]], [[Michael Doukas]], [[Turkan Terkivatan]], [[Diederick Bijdevaate]], [[Robert A. De Man]], [[Adriaan Moelker]] & [[Jan N. IJzermans]]
  | author = [[Maarten G. Thomeer]], [[Mirelle Broker]], [[Joanne Verheij]], [[Michael Doukas]], [[Turkan Terkivatan]], [[Diederick Bijdevaate]], [[Robert A. De Man]], [[Adriaan Moelker]] & [[Jan N. IJzermans]]
  | title = Hepatocellular adenoma: when and how to treat? Update of current evidence
  | title = Hepatocellular adenoma: when and how to treat? Update of current evidence
Line 18: Line 18:
  | pmid = 27803743
  | pmid = 27803743
}}</ref>
}}</ref>
* The [[adenoma]] is < 5 cm in diameter
* It has [[Regression|regressed]] to < 5 cm after discontinuation of [[Oral contraceptive|oral contraceptive medications]].


==References==
==References==

Revision as of 02:23, 23 August 2019

Hepatocellular adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hepatocellular adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatocellular adenoma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatocellular adenoma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatocellular adenoma secondary prevention

CDC on Hepatocellular adenoma secondary prevention

Hepatocellular adenoma secondary prevention in the news

Blogs on Hepatocellular adenoma secondary prevention

Directions to Hospitals Treating Hepatocellular adenoma

Risk calculators and risk factors for Hepatocellular adenoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]

Overview

An annual follow-up with MRI or ultrasound may be scheduled for female patients until menopause.

Secondary Prevention

An annual follow-up with MRI or ultrasound may be scheduled for female patients until menopause, when:[1]

References

  1. Maarten G. Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A. De Man, Adriaan Moelker & Jan N. IJzermans (2016). "Hepatocellular adenoma: when and how to treat? Update of current evidence". Therapeutic advances in gastroenterology. 9 (6): 898–912. doi:10.1177/1756283X16663882. PMID 27803743. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources